Clinicopathological significance of S100A4 expression in non-small cell lung carcinomas

Korean Journal of Pathology

Volumn 44, Issue 5, 2010, Pages 477-482

  Jung, Eun Ah ^a   Cho, Hyun Deuk ^a   Lee, Ji Hye ^a   Oh, Mee Hye ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Carcinoma; Human; Non small cell lung; Prognosis; S100A4 protein

Indexed keywords

EID: 78549282119     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2010.44.5.477     Document Type: Article

References (30)

1. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran: pathologic basis of disease. 8th ed. Philadelphia: Saunders-Elsevier, 2010; 721-31.
2. National Cancer Information Center. Cancer statistics: August 25, 2008 [Internet]. Goyang: National Cancer Information Center; 2008 [cited 2009 Nov 5]. Available from: http://www.cancer.go.kr/cms/statics.
3. Toloza EM, D'Amico TA. Targeted therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2005; 17: 199-204.
4. Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett 2009; 280: 15-30.
5. Cajone F, Sherbet GV. Stathmin is involved in S100A4-mediated regulation of cell cycle progression. Clin Exp Metastasis 1999; 17: 865-71.
6. Jackson-Grusby LL, Swiergiel J, Linzer DI. A growth-related mRNA in cultured mouse cells encodes a placental calcium binding protein. Nucleic Acids Res 1987; 15: 6677-90.
7. Schmidt-Hansen B, Klingelhöfer J, Grum-Schwensen B, et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumorstroma interplay. J Biol Chem 2004; 279: 24498-504.
8. Shi Y, Zou M, Collison K, et al. Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006; 91: 2373-9.
9. Matsumoto K, Irie A, Satoh T, et al. Expression of S100A2 and S100-A4 predicts for disease progression and patient survival in bladder cancer. Urology 2007; 70: 602-7.
10. Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L. The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol 2007; 22: 1025-32.
11. Rudland PS, Platt-Higgins A, Renshaw C, et al. Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000; 60: 1595-603.
12. Lee WY, Su WC, Lin PW, Guo HR, Chang TW, Chen HH. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 2004; 66: 429-38.
13. Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts-1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 2004; 89: 6146-54.
14. Yoon CS, Hyung WJ, Lee JH, et al. Expression of S100A4, E-cadherin, alpha-and beta-catenin in gastric adenocarcinoma. Hepatogastroenterology 2008; 55: 1916-20.
15. Ai KX, Lu LY, Huang XY, Chen W, Zhang HZ. Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol 2008; 14: 1931-5.
16. Kimura K, Endo Y, Yonemura Y, et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000; 16: 1125-31.
17. Matsubara D, Niki T, Ishikawa S, et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their targetgenes. Cancer Sci 2005; 96: 844-57.
18. Tsuna M, Kageyama S, Fukuoka J, et al. Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res 2009; 29: 2547-54.
19. Miyazaki N, Abe Y, Oida Y, et al. Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expression. Int J Oncol 2006; 28: 1369-74.
20. Travis WD. Reporting lung cancer pathology specimens: impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 2009; 54: 3-11.
21. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19: 739-44.
22. Tarabykina S, Griffiths TR, Tulchinsky E, Mellon JK, Bronstein IB, Kriajevska M. Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets 2007; 7: 217-28.
23. Bolander A, Agnarsdóttir M, Wagenius G, et al. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res 2008; 18: 412-9.
24. Kriajevska M, Bronstein IB, Scott DJ, et al. Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphorylation and self-assembly of the heavy chain of nonmuscle myosin. Biochim Biophys Acta 2000; 1498: 252-63.
25. Schäfer BW, Heizmann CW. The S100 family of EF-hand calciumbinding proteins: functions and pathology. Trends Biochem Sci 1996; 21: 134-40.
26. Heizmann CW, Fritz G, Schäfer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002; 7: d1356-68.
27. Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004; 82: 508-15.
28. Grigorian M, Andresen S, Tulchinsky E, et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 2001; 276: 22699-708.
29. Parker C, Lakshmi MS, Piura B, Sherbet GV. Metastasis-associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma. DNA Cell Biol 1994; 13: 343-51.
30. Cho YG, Kim CJ, Nam SW, et al. Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 2005; 11: 4852-6.